GlassScriptPhysician profile
Sankalp Pathak
NPI 1316388234
$11,161.42
in general payments reported to CMS, 2019-2025
38 companies · $695 in 2025
The $695 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $674 · 2020: $2,147 · 2021: $1,495 · 2022: $1,633 · 2023: $2,520 · 2024: $1,996 · 2025: $695.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,191 · Travel and Lodging: $2,021.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,191.18 |
| Travel and Lodging | $2,020.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $4,410.44 | 2019-2025 | Mitraclip, Navitor, Xience Skypoint |
| Medtronic, INC. | $852.30 | 2021-2023 | Corevalve Evolut R |
| Boston Scientific Corporation | $672.11 | 2019-2023 | Watchman Flx |
| Actelion Pharmaceuticals US, INC. | $522.90 | 2020-2022 | |
| Abiomed | $417.32 | 2019-2025 | Impella |
| Novartis Pharmaceuticals Corporation | $382.87 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $367.65 | 2019-2023 | Xarelto |
| Shockwave Medical, INC | $325.96 | 2023-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Intravascular Lithotripsy (Ivl) System With The Shockwave C2+ Coronary |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $286.75 | 2020-2025 | Lifevest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $286.11 | 2019-2025 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $285.38 | 2020-2025 | Camzyos, Eliquis |
| Amgen INC. | $282.43 | 2019-2024 | Repatha |
| Philips North America LLC | $270.79 | 2020-2023 | |
| Astrazeneca Pharmaceuticals LP | $244.34 | 2019-2025 | Farxiga |
| Edwards Lifesciences Corporation | $200.96 | 2023-2025 | Sapien 3 Ultra Resilia, Pascal, Edwards Sapien 3 Ultra Transcatheter Heart Valve |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acist Medical Systems, INC. | $159.54 | 2023 | |
| Heartflow, INC. | $147.94 | 2024 | |
| Pfizer INC. | $146.96 | 2021-2025 | |
| Cordis US Corp. | $129.83 | 2022-2024 | Mynx Venous Vcd |
| Opsens INC. | $114.20 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $78.75 | 2021-2022 | |
| Teleflex LLC | $77.82 | 2022 | |
| Novo Nordisk INC | $72.81 | 2021-2025 | Wegovy |
| Cardiovascular Systems INC. | $64.35 | 2020 | |
| Alnylam Pharmaceuticals INC. | $55.37 | 2025 | Onpattro |
| Lilly USA, LLC | $40.60 | 2025 | Mounjaro, Zepbound |
| Esperion Therapeutics, INC. | $38.49 | 2021 | |
| Sanofi-Aventis U.S. LLC | $31.91 | 2022-2024 | |
| Merck Sharp & Dohme LLC | $31.75 | 2021-2024 | Verquvo |
| Kowa Pharmaceuticals America, INC. | $25.78 | 2021 | |
| Tactile Systems Technology INC | $23.80 | 2025 | Flexitouch Plus, Nimbl |
| Altathera Pharmaceuticals LLC | $20.84 | 2024 | Sotalol Hydrochloride |
| Cvrx, INC. | $18.75 | 2024 | Barostim Neo System |
| Angiodynamics, INC. | $17.02 | 2023 | Auryon Laser System 100-120 Vac |
| Daiichi Sankyo INC. | $16.17 | 2021 | |
| Kiniksa Pharmaceuticals International, Plc | $14.18 | 2024 | Arcalyst |
| Medtronic Vascular, INC. | $13.40 | 2020 | |
| Kiniksa Pharmaceuticals, LTD. | $12.85 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sankalp Pathak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.